Fluticasone ophthalmic - NicOx

Drug Profile

Fluticasone ophthalmic - NicOx

Alternative Names: AC-155; NCX 4251

Latest Information Update: 05 Jun 2015

Price : $50

At a glance

  • Originator Aciex Therapeutics
  • Developer NicOx
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ocular inflammation; Ocular pain

Most Recent Events

  • 05 Jun 2015 NexiCo plans a phase II trial for Blepharitis in USA
  • 27 Oct 2014 Aciex Therapeutics has been acquired by NicOx
  • 08 Oct 2014 Preclinical trials in Ocular inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top